Treatment of HOsPitalised Inpatients for Hepatitis C (TOPIC): Therapeutic Intervention Enhancing Care Linkage in People Who Inject Drugs

Hepatitis C Clinical Trial

— TOPIC  

Official title:

Treatment of HOsPitalised Inpatients for Hepatitis C (TOPIC): Strategic Therapeutic Intervention to Enhance Linkage to Care in People Who Inject Drugs

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03981211
• Other study ID #: VHCRP1902
• Status: Recruiting
• Phase: N/A
• Start date: February 12, 2021
• Est. completion date: February 12, 2025

Study information

• Verified date: December 2023
• Source: Kirby Institute
• Contact: Amanda Erratt
• Phone: 61 2 9385 0882
• Email: aerratt[@]kirby.unsw.edu.au
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will evaluate the proportion of patients achieving confirmed SVR12 (undetectable HCV RNA at time point 12 weeks plus post treatment commencement) in patients hospitalised for IRID (injecting related infectious diseases) and commencing inpatient DAA treatment within public hospital services.

Description:

This study will be conducted as a Phase IV, multicentre, sequential cohort trial.

60 participants will be enrolled from participating hospital inpatient services. They will be evaluated for eligibility by the use of rapid point-of-care (POC) confirmation of viraemia in people who inject drugs (PWID) hospitalised for IRID. The period of hospitalisation for management of IRID, particularly when prolonged, may represent an ideal opportunity to engage HCV-infected PWID and a potential important strategy for broader HCV elimination.

Eligible patients will be enrolled into one of two treatment cohorts A and B.

A) 30 patients will immediately commence treatment whilst an inpatient of G/P (glecaprevir/pibrentasvir) with continuation of therapy and follow-up in viral hepatitis services post discharge (standard duration therapy).

Following the successful completion of Cohort A, eligible patients will be enrolled into Cohort B.

B) 30 patients will immediately commence treatment whilst an inpatient of 4 weeks of SOF/G/P (sofosbuvir/glecaprevir/pibrentasvir) with continuation of therapy and follow-up in viral hepatitis services post discharge (short duration therapy).

Any patient with recurrent viraemia during follow-up will be genotyped +/- sequenced to exclude re-infection. If relapse is confirmed the patient will be offered re-treatment with standard of care (SOC) salvage therapy based on results of resistance testing.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: February 12, 2025
• Est. primary completion date: February 12, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Participants must meet all of the following inclusion criteria to be eligible to participate in this study.

1. Have voluntarily signed the informed consent form.

2. 18 years of age or older.

3. Injected drugs within the last 6 months

4. Hospitalised with an IRID with an anticipated inpatient stay of > 1 week

Participants must meet the following additional inclusion criteria to be treated in this study.

5. HCV RNA positive

6. Compensated liver disease

7. Documented non-cirrhotic at enrolment with a qualifying liver FibroScan = 9.5 kpA

8. If co-infection with HIV is documented, the subject must meet the following criteria:

1. ART naïve with CD4 T cell count >500 cells/mm3; OR

2. On a stable ART regimen (containing only permissible ART) for >4 weeks prior to screening visit, with CD4 T cell count =200 cells/mm3 and a plasma HIV RNA level below the limit of detection.

Exclusion Criteria:

Participants who meet any of the exclusion criteria are not to be enrolled in this study.

1. Inability or unwillingness to provide informed consent or abide by the requirements of the study

2. Actively intoxicated.

Participants that meet any of the additional exclusion criteria are not to be treated in this study.

3. History of any of the following:

b. Clinical hepatic compensation (i.e. ascites, encephalopathy or variceal haemorrhage) c. Solid organ transplant d. History of severe, life-threatening or other significant sensitivity to study drugs (glecaprevir/pibrentasvir/sofosbuvir) or any excipients of the study drugs

4. Creatinine clearance (CLcr) < 30 mL/min at screening (Cohort B only)

5. Pregnant or nursing female

6. Decompensated liver disease

7. Use of prohibited concomitant medications

8. Chronic use of systemically administered immunosuppressive agents (e.g. prednisone equivalent > 10 mg/day for >2 weeks)

9. Prior treatment failure with an NS5A based DAA regimen

Patients without an IRID but who fulfill all other criteria and are admitted with an expected duration of stay > 1 week may also be included at discretion of study team.

Related Conditions & MeSH terms

• Hepatitis
• Hepatitis A
• Hepatitis C
• Inflammation
• Liver Cirrhoses
• Liver Cirrhosis
• Liver Inflammation

Intervention

Drug:
• Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet
8 weeks of 3 x co-formulated tablets of glecaprevir (100mg) and pibrentasvir (40mg) once daily or 4 weeks of 1 tablet sofosbuvir 400 mg and a three fixed-dose combination of glecaprevir/pibrentasvir 100/40 mg tablets administered once daily
• Sofosbuvir 400 MG + Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet
4 weeks of 1 x sofosbuvir (400mg) tablet and 3 x co-formulated tablets of glecaprevir (100mg) and pibrentasvir (40mg) once daily

Locations

Country	Name	City	State
Australia	Royal Adelaide Hospital	Adelaide	South Australia
Australia	St Vincent's Hospital	Melbourne	Victoria
Australia	The Alfred Hospital	Melbourne	Victoria
Australia	Prince of Wales Hospital	Randwick	New South Wales
Australia	Blacktown Mt Druitt Hospital	Sydney	New South Wales
Australia	St Vincent's Hospital Sydney	Sydney	New South Wales
Australia	Westmead Hospital	Westmead	New South Wales

Sponsors (1)

Lead Sponsor	Collaborator
Kirby Institute

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	SVR12 outcomes for all total patient population	To evaluate the proportion of patients achieving confirmed SVR12 (undetectable HCV RNA at time point 12 weeks plus post treatment commencement) in patients hospitalised for IRID and commencing inpatient DAA treatment within public hospital services.	12 weeks post completion of commenced treatment